Case Report

Denosumab Therapy for Giant Cell Tumor of Bone Pulmonary Metastasis

Ryan Carlisle Egbert, Ryan Folsom, Jeff Bell, and Rajiv Rajani

1. Introduction

Giant cell tumor of bone (GCTB) is a benign yet aggressive lytic tumor of bone occurring in the metaphysis and epiphysis of long bones. The most common locations involved are the distal femur, proximal tibia, and distal radius [1]. Such destructive lesions were first described by Cooper and Travers [2] in 1818, but GCTB was not distinguished from other tumors of bone until 1940 [3]. GCTB typically presents in persons 20 to 40 years old and accounts for approximately 20% of all benign tumors of bone [4, 5]. Local recurrence was first described by Virchow [4] and occurs at a rather high rate (18%-50%) [6]. Metastasis occurs rarely, typically in the setting of locally recurrent GCTB. The most common site of metastasis is to the lungs [7]. Metastases are considered benign, are histologically identical to the primary tumor [8], and rarely contribute to death in the majority of patients [7].

The mainstay of treatment of GCTB pulmonary metastasis is surgical [9]. Since pulmonary metastasis of GCTB is rare, there are still no studies comparing different treatment modalities in the current literature. Faisham et al. proposed that aggressive treatment with surgical excision of lung metastasis is mandatory for aggressive GCTB. This is now widely accepted as treatment of choice [10]. Additionally, a case-control study done by Tse et al. suggested medical management as a promising avenue for GCTB treatment [11].

The histologic composition of GCTB consists of sheets of neoplastic spindle shaped mononuclear cells with high levels of RANK Ligand (RANKL) expression, intermixed with large osteoclast giant cells [8, 12]. RANKL potentiates the osteoclast differentiation of monocytes leading to the lytic nature of the tumor [12]. Denosumab is a human monoclonal antibody that inhibits normal and tumor associated RANKL [13–15]. Some studies have shown that denosumab has the ability to prevent tumor progression, induce primary tumor reduction, increase bone formation, and reduce pain in patients with GCTB [16–18]. However, research has not yet shown a definitive role for denosumab in managing pulmonary metastasis of GCTB.
2. Case Report

Our case is a 68-year-old female with a past medical history of hyperlipidemia and insulin-controlled type 2 diabetes mellitus who presented with right knee pain and swelling. She denied any history of trauma. Radiograph and magnetic resonance imaging were concerning for GCTB. She underwent curettage and cementation of the right distal femur lesion and histological examination confirmed the suspected diagnosis of GCTB. Approximately one year later, she developed local recurrence of the tumor, which was also curetted with additional use of cement. One year after the second surgery, a routine chest radiograph showed lung lesions suspicious of metastatic disease (Figure 1). At the time she was feeling well, with only mild pain in her right knee. Computed tomography (CT) imaging verified the presence of several pulmonary nodules including a large right lower lobe (RLL) mass measuring 5.6 cm (Figure 2). CT-guided core needle biopsy of the largest lung mass confirmed metastatic GCTB (Figure 3).

After discussion at a tertiary center musculoskeletal tumor board the patient was started on denosumab therapy. Treatment was initiated with a loading dose of 120 mg every week for three weeks. She was then transitioned to receive a dose of 120 mg every four weeks. She was also placed on daily calcium and vitamin D supplements.

At 3 months after the initiation of treatment she had repeat CT imaging of her chest. The scan showed the RLL mass had decreased considerably in size, now measuring 2.6 cm in its greatest dimension. There was also a decrease in size of the other pulmonary lesions (Figure 2). No new pulmonary nodules were seen. Since then she has had CT imaging of her chest every three months and radiographs of her right knee every six months. She has been without subjective complaint at each follow-up visit. After 16 months of denosumab therapy, a cardiothoracic surgery consultation was obtained and, due to the location and stability of disease, no surgery was recommended. The patient also was adamantly opposed to surgery. She continued to tolerate the denosumab without any evidence of side effects or complications.

Forty-eight months after initiating treatment, CT imaging showed the stable RLL mass as well as the smaller pulmonary lesions to be unchanged in size (Figure 2).

3. Discussion

We present a case of metastatic GCTB successfully treated with denosumab for 4 years. A literature search was able to find only one similar case. This was in a 17-year-old female who was followed for only three months while on denosumab [19]. Our patient has been followed now for over 4 years without signs of disease progression.

Dosing of the denosumab was also different in the two cases. In our patient, we followed the treatment regimen first described by Thomas et al. which consists of three loading doses of 120 mg seven days apart followed by one dose every four weeks [20]. In the case of the 17-year-old female, Demirsoy et al. used a 120 mg monthly dose without loading while achieving similar results of tumor regression [19]. Further studies are required to determine the optimum dose.

A denosumab safety study conducted by Chawla et al. showed low rates of hypocalcemia, osteonecrosis, neutropenia, hypophosphatemia, anemia, back pain, and pain in the extremities [20, 21]. Patients were followed for up to one year. Because of these findings, we supplemented our patient with prophylactic vitamin D and calcium. Our patient has yet to complain of bone pain, back pain, or other symptoms potentially attributable to denosumab therapy. While this treatment may be promising, broader long-term follow-up of patients treated with denosumab would be beneficial.

While denosumab has proven to be effective in reducing metastatic tumor size through interfering with osteoclastic differentiation, it does not target the neoplastic stromal cells, which will continue to proliferate with discontinuation of therapy. It is unknown if patients require chronic denosumab therapy or if the rate of neoplastic stromal cell proliferation can be reduced sufficiently with initial treatment that patients can stop therapy without progression of disease [22]. Recent studies suggest that discontinuation of therapy would lead to regrowth of tumor.

Additionally, there is a theoretical increased risk of pathologic fracture with chronic use of medications similar to bisphosphonates. Therefore, we had considered discontinuing denosumab after three years of therapy. However, due to a report in the literature of critical hypercalcemia following cessation of denosumab [23], the lack of consensus on long-term denosumab therapy [24], and our patient’s lack of adverse effects while on the medication we decided to continue treatment. Also, with our patient refusing surgical excision as a form of treatment, the only options that remain are continuation or cessation of denosumab therapy. At this time, no plans for discontinuation exist.

Other questions concerning denosumab therapy remain. More studies are needed to determine its application in all the stages of GCTB. We are hopeful denosumab can be a reasonable alternative to surgical treatment for pulmonary metastasis [22]. The frequency of dosing and duration of denosumab treatment have yet to be established as well [25]. While denosumab appears effective, further studies are needed to test its superiority over cheaper and more readily available medications [21].
4. Conclusion

Denosumab therapy has promise in the treatment of GCTB, including pulmonary metastasis. However, there is still much to do in defining its use in treating the different stages of GCTB. Also needed are long-term studies further defining its optimum dose, side effects, and how the disease progresses after discontinuation.

Disclosure

A poster version of this manuscript was presented at the University of Texas School of Medicine at San Antonio poster presentation day on April 14, 2015.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

[1] K. A. Raskin, J. H. Schwab, H. J. Mankin, D. S. Springfield, and F. J. Hornicek, “Giant cell tumor of bone,” Journal of the American Academy of Orthopaedic Surgeons, vol. 21, no. 2, pp. 118–126, 2013.

[2] A. Cooper and B. Travers, Surgical Essays: Part I, Cox and Son, London, UK, 2nd edition, 1818.

[3] H. L. Jaffe and R. B. Portis, “Giant cell tumor of bone. Its pathologic appearance, grading,” Arch Pathology, vol. 30, Article ID 993, 1940.

[4] B. L. Coley, Giant Cell Tumor (Osteoclastoma), Neoplasms of Bone and Related Conditions, Hoeber, New York, NY, USA, 1960.

[5] R. D. Lackman, H. S. Hosalkar, C. M. Ogilvie, J. T. Torbert, and E. J. Fox, “Intralesional curettage for grades II and III giant cell tumors of bone,” Clinical Orthopaedics and Related Research, vol. 438, pp. 123–127, 2005.

[6] W. T. Becker, J. Dohle, L. Bernd et al., “Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy,” Journal of Bone and Joint Surgery—Series A, vol. 90, no. 5, pp. 1060–1067, 2008.

[7] M. Balke, L. Schremper, C. Gebert et al., “Giant cell tumor of bone: Treatment and outcome of 214 cases,” Journal of Cancer Research and Clinical Oncology, vol. 134, no. 9, pp. 969–978, 2008.

[8] P. G. Bullough and M. Bansal, “Malignancy in giant cell tumour,” in World Health Organization Classification of Tumours: Pathology And Genetics of Tumours of Soft Tissue And Bone, C. D. M. Fletcher, K. Uitti, and F. Mertens, Eds., International Agency for Research on Cancer (IARC ‘2002), Lyon, France.

[9] J. J. Eckardt and T. J. Grogan, “Giant cell tumor of bone,” Clinical Orthopaedics and Related Research, vol. 204, pp. 45–58, 1986.
[10] W. I. Faisham, W. Zulmi, A. S. Halim, B. M. Biswal, S. S. Mutum, and A. M. Ezane, “Aggressive giant cell tumour of bone,” Singapore Medical Journal, vol. 47, pp. 679–683, 2006.

[11] L. F. Tse, K. C. Wong, S. M. Kumta, L. Huang, T. C. Chow, and J. F. Griffith, “Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: A case-control study,” Bone, vol. 42, no. 1, pp. 68–73, 2008.

[12] M. P. Roudier, K. L. Kellar-Graney, L. Y. Huang et al., “RANK and RANKL expression in giant cell tumours of the bone: an immunohistochemical study,” in Proceedings of the 12th Annual Connective Tissue Oncology Society Meeting, Venice, Italy, 2006.

[13] P. J. Bekker, D. L. Holloway, A. S. Rasmussen et al., “A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women,” Journal of Bone and Mineral Research, vol. 19, no. 7, pp. 1059–1066, 2004.

[14] J.-J. Body, T. Facon, R. E. Coleman et al., “A study of the biological receptor activator of nuclear factor-κ ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer,” Clinical Cancer Research, vol. 12, no. 4, pp. 1221–1228, 2006.

[15] K. Fizazi, A. Lipton, X. Mariette et al., “Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates,” Journal of Clinical Oncology, vol. 27, no. 10, pp. 1564–1571, 2009.

[16] D. Thomas, R. Henshaw, K. Skubitz et al., “Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study,” The Lancet Oncology, vol. 11, no. 3, pp. 275–280, 2010.

[17] D. G. Branstetter, S. D. Nelson, J. C. Manivel et al., “Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone,” Clinical Cancer Research, vol. 18, no. 16, pp. 4415–4424, 2012.

[18] J. Martin-Broto, C. S. Cleeland, P. A. Glare et al., “Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study,” Acta Oncologica, vol. 53, no. 9, pp. 1173–1179, 2014.

[19] U. Demirsoy, M. Karadogan, O. Selek et al., “Golden bullet - Denosumab: Early rapid response of metastatic giant cell tumor of the bone,” Journal of Pediatric Hematology/Oncology, vol. 36, no. 2, pp. 156–158, 2014.

[20] M. Balsek, “Denosumab treatment of giant cell tumour of bone,” The Lancet Oncology, vol. 14, no. 9, pp. 801–802, 2013.

[21] J. W. Y. Mak, N. Evaniw, S. Popovic, R. Tozer, and M. Ghert, “A translational study of the neoplastic cells of giant cell tumour of bone following neoadjuvant denosumab,” The Journal of Bone & Joint Surgery—American Volume, vol. 96, no. 15, article e127, 2014.

[22] N. Gossai, M. V. Hilgers, L. E. Pulgreen, and E. G. Greengard, “Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone,” Pediatric Blood and Cancer, vol. 62, no. 6, pp. 1078–1080, 2015.